THERAPY IN EXPERIMENTAL COCCIDIOIDOMYCOSIS
Abstract
Campbell and Hill (1959) successfully used Fungizone, the presolubilized form of Amphotericin B intended for intravenous therapy, as an oral treatment for experimental coccidioidomycosis in mice. Their work was extended to further study the effects of dose level, length of therapy, and time of initiation of therapy on the course of the disease. A detailed histopathological study was made to compare changes in treated and untreated animals and to uncover possible renal damage resulting from the antibiotic. An oral dose (in the drinking water) of 12 milligrams per kilogram per day, for 20 days, initiated at the time of IP challenge of mice with 1500 Coccidioides immitis arthrospores, resulted in almost no evidence of disease and the absence of positive cultures five months after challenge. Initiation of therapy as late as five or seven days postchallenge exerted a very beneficial effect on the course of the disease. However, per cent mortality, histological changes, and number of animals exhibiting positive cultures of the organism increased in direct proportion to the delay in treatment. No histological evidence of renal damage was noted, even in animals receiving total oral doses of Fungizone as high as three grams (150 milligrams per day for 20 days).
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 1963
- Accession Number
- AD0421563
Entities
People
- E. P. Lowe
- Ernest M. Snyder
- John L. Converse
- Merida W. Castleberry
Organizations
- United States Army Biological Warfare Laboratories